Johnson & Johnson (NYSE:JNJ) recently announced that its Janssen Pharmaceutical Cos. will collaborate with Emergent BioSolutions to support the manufacturing of its lead investigational COVID-19 vaccine candidate.
The New Brunswick, N.J.–based pharmaceutical and medical device giant described the deal as the first in a series of contract manufacturing agreements that it expects to ink as it seeks to eventually supply 1 billion doses of vaccine globally — starting in 2021.
Get the full story at our sister site, Pharmaceutical Processing World.
